Information Density: Amgen (KANJINTI) – Signal Evidence & AI Readability

[IMG: KANJINTI® (trastuzumab-anns) For Injection]

*As of [June 30, 2025]. Number of non-oncology patients calculated from duration of therapy and adherence data from IQVIA Analytics Link and IQVIA Patient Link, respectively. Number of oncology patients determined using claims data (US) and physician surveys (ex-US). Patient count estimates may not accurately reflect the actual number of patients treated with Amgen biosimilars if adherence or length of treatment in real world differs from the assumptions used.

KANJINTI® is indicated for the treatment of:2

HER2-overexpressing breast cancer

HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

KANJINTI® SETS A RIGOROUS STANDARD FOR HERCEPTIN® BIOSIMILARITY

[IMG: The first and only Herceptin® biosimilar with single-transition
study data in the eBC setting]
FDA approved with highly similar safety and efficacy to Herceptin®, with no clinically meaningful differences.2,3
[IMG: btn-medi_rainbow-svg]
totality of evidence

[IMG: Comprehensive support for you and your patients]
Comprehensive support for you and your patients
[IMG: btn-medi_rainbow-svg]
support

[IMG: same support]
Amgen has an incredible track record of reliable supply.4
[IMG: btn-medi_rainbow-svg]
biosimilar expertise

Backed by Amgen Expertise
40+
Years
experience in biologics
[IMG: btn-medi_rainbow-svg]
biosimilar expertise

HER2 = human epidermal growth factor receptor 2; IV = intravenous.

[IMG: AMGEN® Biosimilars]
Get the story behind Amgen's commitment to biosimilars.Amgen Biosimilars

×

Amgen stands with our local Los Angeles community. Click
here to learn what we are doing to support and
contact us if the fires have impacted your access to Amgen medication.

For Patients/ What
Is KANJINTI®
What is
KANJINTI®
Why Amgen Biosimilars
Support
About her2+ Cancer

[H2] There is treatment for your HER2 positive (HER2+) breast OR GASTRIC cancer—and it is
called
KANJINTI®1

[H3] KANJINTI® IS:

Approved by the FDA (Food and Drug Administration) for HER2+ breast and gastric cancer.
KANJINTI® is also known by its chemical name, trastuzumab-anns (trast-OO-zoo-mab).1
A biologic, which is a drug made from a living cell. Biologic medicines are used to treat many
conditions.1,2
[H3] KANJINTI® WORKS WITH YOUR BODY'S IMMUNE SYSTEM TO Help FIGHT CANCER CELLS3

1

[H6] KANJINTI® attaches to HER2 receptors on cells.3

[IMG: How does KANJINTI™ work?]
[H6] NORMAL CELL
Normal cells have some HER2 receptors.4

2

[H6] THIS PREVENTS cancer cells from growing and multiplying.3,*
* Because normal cells have HER2
receptors, KANJINTI® can also prevent their growth and cause serious side effects.

[IMG: How does KANJINTI™ work?]

[H6] HER2+ CANCER CELL
HER2+ cancer cells have many more HER2
receptors than normal cells.4

3

[H6] the cancer cell is then destroyed by the body's defenses.3

[IMG: How does KANJINTI™ work?]

[H6] HER2+ CANCER CELL

[IMG: First KANJINTI]
KANJINTI®®

[H2] WhY KANJINTI®?

[H3] PROVEN TO BE AS EFFECTIVE AS HERCEPTIN®
KANJINTI® is a biosimilar to the cancer drug Herceptin® and is FDA-approved
for the same uses. KANJINTI® has been tested worldwide and has been proven
to have similar side effects as
Herceptin®.1,5

[H3] CAN I BE GIVEN KANJINTI® IF I'VE ALREADY STARTED WITH
HERCEPTIN®?

[IMG: single transition]

[IMG: single transition]

[H3] CAN I BE GIVEN KANJINTI® IF I'VE ALREADY STARTED WITH HERCEPTIN®?
KANJINTI® has been proven to be as effective as Herceptin® in a study. Some
patients in this study started treatment with Herceptin®, then were transitioned
to KANJINTI® for the rest of the study
to make sure the side effects were
similar compared with patients who only took KANJINTI® for the length of the study.5

[IMG: Proven similar to Herceptin]

[IMG: Clinically studied with patients worldwide]
[H3] A few things to keep in mind as you start KANJINTI®
Now that you know more about HER2+ breast and gastric cancer and KANJINTI®, you may have some
questions about starting this course of therapy.

[IMG: How is KANJINTI® Prescribed?]

[H2] KANJINTI® may be prescribed alone or with chemotherapy.1

Your doctor may choose to use KANJINTI® with or without chemotherapy. Your doctor or nurse
will discuss which combination of treatments is right for you.

[IMG: KANJINTI® Infusion]

[H2] KANJINTI® is given through an infusion.1

You will receive KANJINTI® either once a week or once every 3 weeks for as long as your doctor
thinks it is working for you and as long as you are not having any serious side effects.1

The points above offer only an outline of what you might expect when starting KANJINTI®. Your
doctor will make these treatment decisions with you. If your treatment plan is not clear, please talk with your
treatment team.

[H2] REGULAR HEART MONITORING IS IMPORTANT1
Per standard treatment with KANJINTI®, and similar drugs like Herceptin®, you will
receive regular heart function checkups. These checkups occur throughout the course of your treatment.1 Heart
function will be tested with an ECHO or MUGA scan.1 An ECHO scan is an ultrasound image of the heart. A MUGA scan
takes a moving picture of your heart pumping blood.6

[IMG: KANJINTI® and Heart Monitoring]
BEFORE
Starting
KANJINTI®
every 3–4 MONTHS During & upon completion of KANJINTI® TReatment
every 6 MONTHS for at least 2 years after completing KANJINTI® therapy

[IMG: KANJINTI® and Heart Monitoring]
ECHO = electrocardiogram; HER2 = human epidermal growth factor receptor 2; MUGA = multigated blood-pool
imaging.
[H2] What to look out for
You should tell your doctor or nurse as soon as possible if you feel unwell or develop the following:1
Breathlessness and cough
Swelling in your ankles/legs or face
Feeling your heart flutter or an irregular heartbeat
Weight gain of more than 5 pounds in 24 hours
Dizziness or loss of consciousness
Be sure to review the Important
Safety Information to learn more
about potential side effects and symptoms you need to watch for to help your doctor know when you are having a
side effect

×

Amgen stands with our local Los Angeles community. Click
here to learn what we are doing to support and
contact us if the fires have impacted your access to Amgen medication.

Amgen is a leader in biologics with a growing portfolio of biosimilars.

[H2] HERITAGE

[H4] The healthcare community has been able to trust us for decades

[IMG: AMGEN Biologics – over 40 years of experience]

[IMG: AMGEN Biologics – over 40 years of experience]

[IMG: AMGEN Biologics – over 40 years of experience]

AT AMGEN, WE’RE COMMITTED TO DELIVERING QUALITY PRODUCTS
TO EVERY PATIENT, EVERY TIME

[H2] EXPERTISE
[H4] Real-world experience and expertise paved the way for our leadership in biosimilars
[IMG: Over 300 Quality Checks During Manufacturing]
[IMG: Over 300 Quality Checks During Manufacturing]
*Available biosimilars across all global markets.
†As of [June 30, 2025]. Number of non-oncology patients calculated from duration of therapy and adherence data from IQVIA Analytics Link and IQVIA Patient Link, respectively. Number of oncology patients determined using claims data (US) and physician surveys (ex-US). Patient count estimates may not accurately reflect the actual number of patients treated with Amgen biosimilars if adherence or length of treatment in real world differs from the assumptions used.

[H2] Commitment
[H4] WE ARE A LONG-STANDING BIOTECHNOLOGY LEADER COMMITTED TO DEVELOPING THE BIOSIMILAR MARKETPLACE
Invested in the development of biosimilars and novel therapeutics
[IMG: In the last decade, AMGEN® has achieved zero supply shortages]
[IMG: In the last decade, AMGEN® has achieved zero supply shortages]

[H2] Support

[H4] WE ARE COMMITTED TO PROVIDING SOLUTION-ORIENTED RESOURCES THAT CAN HELP PROVIDE POSITIVE BIOSIMILAR EXPERIENCES

[IMG: Amgen Support]

[IMG: Amgen Support]

[IMG: AMGEN® Biosimilars]
Learn more about Amgen’s commitment to biosimilars.Amgen Biosimilars

Learn how Amgen uses the same support programs
for KANJINTI® as we do for our innovative treatments.
[IMG: btn-medi_rainbow-svg]
support

[IMG: amgen-oncology_logo]
To stay up-to-date on Amgen’s advances in oncology,
visit AmgenOncology.com.Amgen Biosimilars

×

Amgen stands with our local Los Angeles community. Click
here to learn what we are doing to support and
contact us if the fires have impacted your access to Amgen medication.

KANJINTI® PROVIDES IDENTICAL DOSING TO HERCEPTIN® IV ACROSS ALL
INDICATIONS
Dosing similarity is one of several ways Amgen helps provide you and your patients with
a seamless
experience.1,2
[IMG: kanjinti dosing with paclitaxel or docetaxel for adjuvant
treatment]
[IMG: kanjinti dosing with docetaxel and carboplatin for adjuvant
treatment]
[IMG: kanjinti dosing as single agent for adjuvant treatment]
[IMG: kanjinti dosing as single agent or with paclitaxel for breast cancer]
[IMG: kanjinti dosing as single agent or for gastric cancer]
[IMG: kanjinti dosing with paclitaxel or docetaxel for adjuvant
treatment]
[IMG: kanjinti dosing with docetaxel and carboplatin for adjuvant
treatment]
[IMG: kanjinti dosing as single agent for adjuvant treatment]
[IMG: kanjinti dosing as single agent or with paclitaxel for breast cancer]
[IMG: kanjinti dosing as single agent or for gastric cancer]
IV = intravenous; QW = once a week; Q3W = once every 3 weeks.
Please refer to accompanying full Prescribing Information for complete dosing and administration guidelines.
[IMG: 1M+ Patients]
[IMG: Available 150 mg and 420 mg vials]
[IMG: KANJINTI® 150mg and 420 mg vials]
IV = intravenous; QW = once a week; Q3W = once every 3 weeks.
Please refer to accompanying full Prescribing Information for complete dosing and administration guidelines.
KANJINTI® has the same
dosing as Herceptin® IV
across all indications1,2
*Within 3 weeks following completion
lof all chemotherapy.
†EU-sourced Herceptin® was used in
the LILAC study. The KANJINTI®
clinical pharmacokinetic (PK) study demonstrated equivalence between
EU- and US-sourced Herceptin® and KANJINTI®.

See how KANJINTI® is proven biosimilar to Herceptin®.†
[IMG: btn-medi_rainbow-svg]
totality of evidence

*Within 3 weeks following completion of all chemotherapy.
†EU-sourced Herceptin® was used in
the LILAC study. The KANJINTI®
clinical pharmacokinetic (PK) study demonstrated equivalence between
EU- and US-sourced Herceptin® and KANJINTI®.

×

Amgen stands with our local Los Angeles community. Click
here to learn what we are doing to support and
contact us if the fires have impacted your access to Amgen medication.